Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30136009 | 0.89 | SOS1 (0.44) | DRD2SOS1DDB1CRBNNR3C1 | |
| SCHEMBL25583436 | 0.88 | SOS1 (0.44) | SOS1DDB1CRBNNR3C1PGR | |
| SCHEMBL30278924 | 0.87 | DRD2 (0.47) | DRD2SOS1DDB1CRBNNR3C1 | |
| SCHEMBL31255369 | 0.85 | MEN1 (0.46) | SOS1DDB1CRBNCFTRNAMPT | |
| SCHEMBL25941898 | 0.85 | DRD2 (0.46) | DRD2SOS1DRD3DDB1CRBN | |
| SCHEMBL30984835 | 0.84 | SOS1 (0.51) | SOS1DDB1CRBNNR3C1PGR | |
| SCHEMBL24735135 | 0.84 | DDB1 (0.47) | DRD2SOS1DRD3DDB1CRBN | |
| SCHEMBL30135978 | 0.83 | DDB1 (0.39) | DRD2SOS1DDB1CRBNNR3C1 | |
| SCHEMBL30501235 | 0.83 | SOS1 (0.46) | SOS1NR3C1PGRSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL30278940 | 0.83 | SOS1 (0.45) | SOS1NR3C1PGRSLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DRD2 4476/4885SOS1 2837/4885DRD3 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.